azelnidipine has been researched along with Diabetes Mellitus, Adult-Onset in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (30.00) | 29.6817 |
| 2010's | 7 (70.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dohi, Y; Hirota, H; Isaka, N; Ito, M; Kato, T; Kimura, G; Kojima, M; Machida, H; Makino, K; Miyagawa, K; Mizubayashi, R; Mizuno, O; Nakatani, K; Okamoto, S; Okubo, S; Okura, T; Takeuchi, M | 1 |
| Kawasaki, S; Kimura, M; Kondo, Y; Nakamura, A; Takihata, M; Terauchi, Y | 1 |
| Fukui, M; Hasegawa, G; Matsumoto, S; Nakamura, N; Oyabu, C; Tanaka, M; Ushigome, E; Ushigome, H; Yamazaki, M; Yokota, I | 1 |
| Iwamoto, Y; Katayama, S; Kawamori, R; Kuramoto, K; Saito, I | 1 |
| Abe, M; Maruyama, N; Matsumoto, K; Matsumoto, S; Okada, K; Soma, M | 1 |
| Hayashi, K | 1 |
| Arakawa, K; Jinnouchi, H; Jinnouchi, T; Kim-Mitsuyama, S; Matsui, K; Ogawa, H | 1 |
| Daikuhara, H; Ishida, T; Kikuchi, F | 1 |
| Chen, R; Horiuchi, M; Iwai, M; Li, HS; Li, JM; Min, LJ; Mogi, M; Shiuchi, T; Suzuki, J; Tomochika, H; Tomono, Y; Tsuda, M; Wu, L | 1 |
| Fujitani, Y; Hirose, T; Kanazawa, A; Kawamori, R; Ohmura, C; Sakai, K; Shimizu, T; Uchino, H; Watada, H | 1 |
7 trial(s) available for azelnidipine and Diabetes Mellitus, Adult-Onset
| Article | Year |
|---|---|
Kidney-protective effects of azelnidipine versus a diuretic in combination with olmesartan in hypertensive patients with diabetes and albuminuria: a randomized study.
Topics: Adult; Aged; Albuminuria; Antihypertensive Agents; Azetidinecarboxylic Acid; Calcium Channel Blockers; Diabetes Complications; Diabetes Mellitus, Type 2; Dihydropyridines; Drug Therapy, Combination; Female; Follow-Up Studies; Glomerular Filtration Rate; Humans; Hypertension; Imidazoles; Kidney Diseases; Male; Middle Aged; Prognosis; Prospective Studies; Risk Factors; Tetrazoles; Young Adult | 2013 |
Comparison of Azelnidipine and Trichlormethiazide in Japanese Type 2 Diabetic Patients with Hypertension: The COAT Randomized Controlled Trial.
Topics: Aged; Azetidinecarboxylic Acid; Blood Pressure; Calcium Channel Blockers; Diabetes Mellitus, Type 2; Dihydropyridines; Diuretics; Female; Humans; Hypertension; Japan; Male; Middle Aged; Risk Factors; Treatment Outcome; Trichlormethiazide | 2015 |
In half of hypertensive diabetics, co-administration of a calcium channel blocker and an angiotensin-converting enzyme inhibitor achieved a target blood pressure of <130/80 mmHg: the azelnidipine and temocapril in hypertensive patients with type 2 diabete
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Azetidinecarboxylic Acid; Blood Glucose; Blood Pressure; Calcium Channel Blockers; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dihydropyridines; Drug Therapy, Combination; Female; Heart Rate; Humans; Hypertension, Renal; Kidney Function Tests; Lipids; Male; Middle Aged; Thiazepines; Treatment Outcome | 2008 |
Additive antioxidative effects of azelnidipine on angiotensin receptor blocker olmesartan treatment for type 2 diabetic patients with albuminuria.
Topics: Aged; Albuminuria; Aldosterone; Angiotensin II Type 1 Receptor Blockers; Azetidinecarboxylic Acid; Blood Pressure; Calcium Channel Blockers; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dihydropyridines; Drug Therapy, Combination; Female; Humans; Hypertension; Imidazoles; Male; Middle Aged; Tetrazoles | 2011 |
Angiotensin II receptor blocker-based therapy in Japanese elderly, high-risk, hypertensive patients.
Topics: Aged; Aged, 80 and over; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Azetidinecarboxylic Acid; Calcium Channel Blockers; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dihydropyridines; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hypertension; Imidazoles; Japan; Male; Prospective Studies; Single-Blind Method; Survival Analysis; Tetrazoles; Treatment Outcome | 2012 |
The combination of OLmesartan and a CAlcium channel blocker (azelnidipine) or candesartan and a calcium channel blocker (amlodipine) in type 2 diabetic hypertensive patients: the OLCA study.
Topics: Aged; Albuminuria; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Azetidinecarboxylic Acid; Benzimidazoles; Biomarkers; Biphenyl Compounds; Blood Glucose; Blood Pressure; Calcium Channel Blockers; Chi-Square Distribution; Diabetes Mellitus, Type 2; Dihydropyridines; Drug Therapy, Combination; Female; Glycated Hemoglobin; Heart Rate; Humans; Hypertension; Imidazoles; Japan; Male; Middle Aged; Tetrazoles; Time Factors; Treatment Outcome | 2012 |
Calcium channel blocker, azelnidipine, reduces lipid hydroperoxides in patients with type 2 diabetes independent of blood pressure.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Ascorbic Acid; Azetidinecarboxylic Acid; Blood Pressure; Calcium Channel Blockers; Diabetes Mellitus, Type 2; Dihydropyridines; Erythrocytes; Female; Humans; Hypertension; Lipid Peroxides; Male; Middle Aged; Organophosphorus Compounds; Pyrenes; Vitamin E | 2007 |
3 other study(ies) available for azelnidipine and Diabetes Mellitus, Adult-Onset
| Article | Year |
|---|---|
Olmesartan with azelnidipine versus with trichlormethiazide on home blood pressure variability in patients with type II diabetes mellitus.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Azetidinecarboxylic Acid; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Calcium Channel Blockers; Cross-Over Studies; Diabetes Mellitus, Type 2; Dihydropyridines; Diuretics; Drug Therapy, Combination; Female; Humans; Hypertension; Imidazoles; Male; Middle Aged; Pilot Projects; Tetrazoles; Trichlormethiazide | 2017 |
L-/T-type Ca channel blockers for kidney protection: ready for sophisticated use of Ca channel blockers.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Azetidinecarboxylic Acid; Calcium Channel Blockers; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dihydropyridines; Female; Humans; Hypertension; Imidazoles; Male; Tetrazoles | 2011 |
Calcium channel blocker azelnidipine reduces glucose intolerance in diabetic mice via different mechanism than angiotensin receptor blocker olmesartan.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antimetabolites; Antioxidants; Azetidinecarboxylic Acid; Blood Glucose; Calcium Channel Blockers; Cyclic N-Oxides; Deoxyglucose; Diabetes Mellitus, Type 2; Dihydropyridines; Glucose Intolerance; Glucose Tolerance Test; Glucose Transporter Type 4; Imidazoles; Insulin; Insulin Receptor Substrate Proteins; Male; Mice; Mice, Inbred C57BL; Oxidative Stress; Phosphoproteins; Spin Labels; Superoxides; Tetrazoles | 2006 |